Back to Browse Journals » International Journal of General Medicine » Volume 1

A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia

Authors Amy S Chappell, Laurence A Bradley, Curtis Wiltse, Michael J Detke, Deborah N D’Souza, Michael Spaeth

Published 9 December 2008 Volume 2008:1 Pages 91—102


Review by Single-blind

Peer reviewer comments 2

Amy S Chappell1, Laurence A Bradley2, Curtis Wiltse1, Michael J Detke1,3,4, Deborah N D’Souza1, Michael Spaeth5

1Lilly Research Laboratories, Indianapolis, IN, USA; 2University of Alabama at Birmingham, Birmingham, Alabama, USA; 3Indiana University School of Medicine, Indianapolis, IN, USA; 4Harvard Medical School, Boston, MA, USA; 5Practice for Internal Medicine/Rheumatology, Graefelfing, Germany

Objective: Assess the efficacy of duloxetine 60/120 mg (N = 162) once daily compared with placebo (N = 168) in the treatment of patients with fibromyalgia, during six months of treatment.

Methods: This was a phase-III, randomized, double-blind, placebo-controlled, parallel-group study assessing the efficacy and safety of duloxetine.

Results: There were no significant differences between treatment groups on the co-primary efficacy outcome measures, change in the Brief Pain Inventory (BPI) average pain severity from baseline to endpoint (P = 0.053) and the Patient’s Global Impressions of Improvement (PGI-I) at endpoint (P = 0.073). Duloxetine-treated patients improved significantly more than placebo-treated patients on the Fibromyalgia Impact Questionnaire pain score, BPI least pain score and average interference score, Clinical Global Impressions of Severity scale, area under the curve of pain relief, Multidimensional Fatigue Inventory mental fatigue dimension, Beck Depression Inventory-II total score, and 36-item Short Form Health Survey mental component summary and mental health score. Nausea was the most common treatment-emergent adverse event in the duloxetine group. Overall discontinuation rates were similar between groups.

Conclusions: Although duloxetine 60/120 mg/day failed to demonstrate significant improvement over placebo on the co-primary outcome measures, in this supportive study, duloxetine demonstrated significant improvement compared with placebo on numerous secondary measures.

Keywords: fibromyalgia, duloxetine, placebo, double-blind, trial, pain

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

Altered diastolic function and aortic stiffness in Alzheimer’s disease

Çalık AN, Özcan KS, Yüksel G, Güngör B, Aruğarslan E, Varlibas F, Ekmekci A, Osmonov D, Tatlısu MA, Karaca M, Bolca O, Erdinler I

Clinical Interventions in Aging 2014, 9:1115-1121

Published Date: 16 July 2014

Physical activity and cognitive function in individuals over 60 years of age: a systematic review

Carvalho A, Rea IM, Parimon T, Cusack BJ

Clinical Interventions in Aging 2014, 9:661-682

Published Date: 12 April 2014

The association of C3435T single-nucleotide polymorphism, Pgp-glycoprotein gene expression levels and carbamazepine maintenance dose in patients with epilepsy

Sterjev Z, Trencevska GK, Cvetkovska E, Petrov I, Kuzmanovski I, Ribarska JT, Nestorovska AK, Matevska N, Naumovska Z, Jolevska-Trajkovic S, Dimovski A, Suturkova L

Neuropsychiatric Disease and Treatment 2012, 8:191-196

Published Date: 19 April 2012

Pharmacokinetics of iron isomaltoside 1000 in patients with inflammatory bowel disease

Nordfjeld K, Andreasen H, Thomsen LL

Drug Design, Development and Therapy 2012, 6:43-51

Published Date: 5 March 2012


Krikeli M, Ekonomopoulou MT, Tzitzikas I, Goutzioulis A, Mystakidou K, Pistevou-Gompaki K

Cancer Management and Research 2011, 3:319-320

Published Date: 5 December 2011

Treatment strategies in mucous membrane pemphigoid

Ann G Neff, Matthew Turner, Diya F Mutasim

Therapeutics and Clinical Risk Management 2008, 4:617-626

Published Date: 6 June 2008

Review of botulinum toxin type A for the prophylactic treatment of chronic daily headache

Stefan Evers

Neuropsychiatric Disease and Treatment 2007, 3:761-764

Published Date: 15 January 2008

Agomelatine and its therapeutic potential in the depressed patient

Sidney H Kennedy, Beata S Eisfeld

Neuropsychiatric Disease and Treatment 2007, 3:423-428

Published Date: 15 September 2007